{"classes":[{"categories":[{"measurements":[{"comment":"Due to the small sample size (n = 14) the upper confidence limit was not estimable (did not cross the 50% line)","groupId":"OG000","lowerLimit":"1.3","upperLimit":"NA","value":"3.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Participants who progress during treatment and are found to be part of the gemcitabine+placebo arm after unblinding are eligible to receive open-label pazopanib with gemcitabine. This is the crossover population. Statistical analysis is exploratory and requires sufficient crossover participants to assess Kaplan-Meier estimated hazard ratio and associated 95% confidence interval. This represents the participants second progression. In both cases progression is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 as at least a 20% increase in the sum of the longest diameters of target lesions with an absolute increase of at least 5 mm (target lesions), or measurable increase in non-target lesions (unequivocal progression), or appearance of one or more new lesions. First progression uses the smallest sum on study as a reference; progression for the crossover population uses first progression measurements as the reference.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to the gemcitabine + placebo arm who progressed can be moved into the crossover arm, receiving gemcitabine + open-label pazopanib","id":"OG000","title":"Crossover From Gemcitabine + Placebo to Gemcitabine + Open-label Pazopanib"}],"paramType":"MEDIAN","populationDescription":"Participants randomized to the gemcitabine + placebo arm who progressed and elected to receive gemcitibine + open-label pazopanib","reportingStatus":"POSTED","timeFrame":"Calculated as the time from receiving open-labeled pazopanib hydrochloride to the next documented progression or death whichever occurs first, assessed up to 3 years","title":"Progression-free Survival (PFS) for a Sub-group of Patients Treated With Open-label Pazopanib Hydrochloride Following Administration of Gemcitabine Hydrochloride in the Cross-over Portion of This Study","type":"SECONDARY","unitOfMeasure":"months"}